Reuters logo
BRIEF-Coherus Biosciences receives decision denying institution of '166 IPR related to AbbVie's Humira formulation
November 7, 2016 / 5:56 PM / in a year

BRIEF-Coherus Biosciences receives decision denying institution of '166 IPR related to AbbVie's Humira formulation

Nov 7 (Reuters) - Coherus Biosciences Inc

* Coherus biosciences receives decision denying institution of the ‘166 IPR related to AbbVie’s Humira formulation

* “Coherus remains committed to launching our Humira biosimilar once approved” Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below